Black Diamond Therapeutics Announces the Appointment of Fang Ni as Chief Business Officer
CAMBRIDGE, Mass. and NEW YORK, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of
small molecule, tumor-agnostic therapies, today announced the appointment of Fang Ni, Pharm.D., as Chief Business Officer.
“Fang’s proven track record in business development and corporate strategy, including his work as Black Diamond’s interim Chief Business Officer, gives us confidence that he has the optimal expertise to expand and execute our strategic and business development initiatives,” said David M. Epstein, Ph.D., President and Chief Executive Officer of Black Diamond Therapeutics. “Fang’s leadership of this critical function will be key as we advance our pipeline of clinical and discovery programs derived from the MAP platform.”
“Black Diamond has pioneered a highly differentiated approach to drug discovery and development wherein population-level genomic data is integrated into discovery programs to identify, validate, and target entire oncogene mutation families,” said Fang. “I look forward to realizing the full potential of our platform by exploring new opportunities across our deep pipeline.”
Fang joins Black Diamond most recently from Versant Ventures, where he served as Principal and member of the investment team. He was Black Diamond’s founding Chief Business Officer following the Company’s Versant-led Series A financing, making critical contributions to Black Diamond’s corporate and business strategy. While at Versant, Fang also served as Interim Chief Business Officer for several new ventures, including Monte Rosa Therapeutics and Bright Peak Therapeutics. He was previously a Global Business Development & Licensing director within Roche’s Partnering organization, where he was responsible for leading transactions across oncology, immunology, and infectious and rare diseases. Fang earned a Doctor of Pharmacy degree from Purdue University and then completed a post-doctoral fellowship at Rutgers University.
Lesen Sie auch
About Black Diamond
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with
genetically defined cancers. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology
platform, Mutation-Allostery-Pharmacology (MAP) platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer
across tumor types, group these mutations into families, and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond was
founded by David M. Epstein, Ph.D. and Elizabeth Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began building the MAP platform and chemistry discovery engine. For more
information, please visit www.blackdiamondtherapeutics.com.